Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Hörnberg, Emma ^a   Ylitalo, Erik Bovinder ^a   Crnalic, Sead ^a   Antti, Henrik ^a   Stattin, Pär ^a   Widmark, Anders ^a   Bergh, Anders ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; MESSENGER RNA; ISOPROTEIN; LIGAND;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CASTRATION; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; PRIMARY TUMOR; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BONE TUMOR; CELL CYCLE; CELL NUCLEUS; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; ORCHIECTOMY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE; SURVIVAL;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CELL CYCLE; CELL NUCLEUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MIDDLE AGED; ORCHIECTOMY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 79955719838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019059     Document Type: Article

References (28)

1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
2. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, et al. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227.
3. Crnalic S, Hornberg E, Wikstrom P, Lerner UH, Tieva A, et al. (2010) Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr Relat Cancer 17: 885-895.
4. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
5. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
6. Chen Y, Clegg NJ, Scher HI, (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10: 981-991.
7. Gelmann EP, (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015.
8. Jenster G, van der Korput HA, Trapman J, Brinkmann AO, (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270: 7341-7346.
9. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, et al. (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614.
10. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, et al. (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108: 152-157.
11. Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, et al. (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121: 1238-1244.
12. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ, (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
14. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
15. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, et al. (2010) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31: 74-80.
16. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
17. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
18. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, et al. (2004) Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 64: 5664-5671.
19. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, et al. (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90: 2317-2325.
20. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489-1495.
21. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
22. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, et al. (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
23. Mashima T, Okabe S, Seimiya H, (2010) Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Mol Pharmacol 78: 846-854.
24. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17: 535-546.
25. D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, et al. (2010) Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One 5: e11475.
26. Landstrom M, Damber JE, Bergh A, (1994) Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res 54: 4281-4284.
27. Denmeade SR, Lin XS, Isaacs JT, (1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265.
28. Koh C, Bieberich C, Dang C, Nelson W, Yegnasubramanian S, et al. (2010) MYC and Prostate Cancer Genes & Cancer: pp. 617-628.